| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute hyperosmolar hyperglycaemic state in cystic fibrosis-related diabetes caused by glucocorticoid and itraconazole interaction
|
Bernhardt, Isaac T
|
|
|
20 |
2 |
p. 330-332
|
artikel
|
| 2 |
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation
|
McKone, Edward F.
|
|
|
20 |
2 |
p. 234-242
|
artikel
|
| 3 |
Azithromycin and tezacaftor/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis
|
Song, Yang
|
|
|
20 |
2 |
p. e19-e21
|
artikel
|
| 4 |
Citrullination of extracellular histone H3.1 reduces antibacterial activity and exacerbates its proteolytic degradation
|
Tanner, Lloyd
|
|
|
20 |
2 |
p. 346-355
|
artikel
|
| 5 |
Clinical characteristics and outcomes associated with Inquilinus infection in cystic fibrosis
|
Lenhart-Pendergrass, Patricia M.
|
|
|
20 |
2 |
p. 310-315
|
artikel
|
| 6 |
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
|
Burgel, Pierre-Régis
|
|
|
20 |
2 |
p. 220-227
|
artikel
|
| 7 |
Delayed glucose peak and elevated 1-hour glucose on the oral glucose tolerance test identify youth with cystic fibrosis with lower oral disposition index
|
Tommerdahl, Kalie L.
|
|
|
20 |
2 |
p. 339-345
|
artikel
|
| 8 |
Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics
|
Daboor, Said M.
|
|
|
20 |
2 |
p. 264-270
|
artikel
|
| 9 |
Ebselen attenuates tobramycin-induced ototoxicity in mice
|
Gu, Rende
|
|
|
20 |
2 |
p. 271-277
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
20 |
2 |
p. ii
|
artikel
|
| 11 |
Erratum to ‘From micro to macro; joining the dots of early CF lung disease’ [Journal of Cystic Fibrosis (2020) 850–851/2102]
|
Linnane, Barry
|
|
|
20 |
2 |
p. 374
|
artikel
|
| 12 |
First and second wave of SARS-CoV2 in Italian Cystic Fibrosis patients: Data from Italian Cystic Fibrosis Registry
|
Padoan, Rita
|
|
|
20 |
2 |
p. 372-373
|
artikel
|
| 13 |
Growing mold together–moving beyond standard cultures in assessing fungi in the CF airway
|
Rey, Michael M.
|
|
|
20 |
2 |
p. 191-192
|
artikel
|
| 14 |
Impact of biofilm formation and azoles' susceptibility in Scedosporium/Lomentospora species using an in vitro model that mimics the cystic fibrosis patients' airway environment
|
Mello, Thaís P.
|
|
|
20 |
2 |
p. 303-309
|
artikel
|
| 15 |
Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis
|
Magaret, Amalia S.
|
|
|
20 |
2 |
p. e16-e18
|
artikel
|
| 16 |
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation
|
Guimbellot, J.S.
|
|
|
20 |
2 |
p. 213-219
|
artikel
|
| 17 |
Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry
|
Kaplan, Sigal
|
|
|
20 |
2 |
p. 324-329
|
artikel
|
| 18 |
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients
|
Moheet, Amir
|
|
|
20 |
2 |
p. 333-338
|
artikel
|
| 19 |
News article
|
|
|
|
20 |
2 |
p. 193-194
|
artikel
|
| 20 |
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation
|
Harruff, E. Emily
|
|
|
20 |
2 |
p. 288-294
|
artikel
|
| 21 |
Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis
|
Stanojevic, Sanja
|
|
|
20 |
2 |
p. 243-249
|
artikel
|
| 22 |
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
|
Nichols, Dave P.
|
|
|
20 |
2 |
p. 205-212
|
artikel
|
| 23 |
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin
|
Garinis, Angela
|
|
|
20 |
2 |
p. 278-283
|
artikel
|
| 24 |
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis
|
VanDevanter, Donald R.
|
|
|
20 |
2 |
p. 257-263
|
artikel
|
| 25 |
Psychological distress in adults with and without cystic fibrosis during the COVID-19 lockdown
|
Ciprandi, Riccardo
|
|
|
20 |
2 |
p. 198-204
|
artikel
|
| 26 |
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial
|
Puvvadi, Ramaa
|
|
|
20 |
2 |
p. 316-323
|
artikel
|
| 27 |
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)
|
Kazani, Shamsah
|
|
|
20 |
2 |
p. 250-256
|
artikel
|
| 28 |
Significant functional differences in differentiated Conditionally Reprogrammed (CRC)- and Feeder-free Dual SMAD inhibited-expanded human nasal epithelial cells
|
Awatade, Nikhil T.
|
|
|
20 |
2 |
p. 364-371
|
artikel
|
| 29 |
Successful biodegradable stent insertion in an infant with severe bronchomalacia and cystic fibrosis
|
Harris, Caroline A.
|
|
|
20 |
2 |
p. e13-e15
|
artikel
|
| 30 |
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
|
Schwarz, Carsten
|
|
|
20 |
2 |
p. 228-233
|
artikel
|
| 31 |
The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis
|
Cuthbertson, Leah
|
|
|
20 |
2 |
p. 295-302
|
artikel
|
| 32 |
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network
|
Pearson, Kelsie
|
|
|
20 |
2 |
p. 195-197
|
artikel
|
| 33 |
The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis
|
Elson, E. Claire
|
|
|
20 |
2 |
p. 284-287
|
artikel
|
| 34 |
The march towards CFTR modulator access for all people with CF: The end of the beginning
|
VanDevanter, Donald R
|
|
|
20 |
2 |
p. 185-187
|
artikel
|
| 35 |
The proteostatic network chaperome is downregulated in F508del homozygote cystic fibrosis
|
Sala, Marc A.
|
|
|
20 |
2 |
p. 356-363
|
artikel
|
| 36 |
Tribulations and (clinical) trials in cystic fibrosis
|
Cagnina, R. Elaine
|
|
|
20 |
2 |
p. 188-190
|
artikel
|
Tijdschrift beschrijving